In summary, our data show that FLI1 expression is commonly downregulated in gastric cancers, support a combined role for FLI1 as a suppressor of invasiveness and proliferation in gastric cancer, in particular in the transition from pre-cancer lesions (IM and dysplasia) to invasive adenocarcinoma, and suggest that FLI1 may be a prognostic biomarker of survival in specific sub-groups of gastric cancers. This evidence concerns the gene FLI1 and dysplasia.